FBR & Co started coverage on shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in a report released on Thursday. The firm issued a buy rating and a $53.00 target price on the specialty pharmaceutical company’s stock. FBR & Co also issued estimates for Supernus Pharmaceuticals’ Q3 2017 earnings at $0.28 EPS, Q4 2017 earnings at $0.25 EPS, FY2017 earnings at $1.05 EPS, Q1 2018 earnings at $0.27 EPS, Q2 2018 earnings at $0.42 EPS, Q3 2018 earnings at $0.48 EPS, Q4 2018 earnings at $0.53 EPS and FY2018 earnings at $1.70 EPS.

“We are initiating coverage of Supernus Pharmaceuticals (SUPN) with a Buy rating and a 12-month price target of $53 per share. We see strong revenue growth exceeding 25% per year for 2017–2019 with in-line drugs Trokendi XR (epilepsy/ migraine) and Oxtellar XR (epilepsy) driving growth. Starting in 2020, we expect contribution from late-stage pipeline drugs SPN-812, which is a non-stimulant ADHD drug, and SPN-810 for impulsive aggression. We model EPS at $1.05 in 2017, $1.70 in 2018, and $2.35 in 2019 including a full tax rate. Our 2017 EPS estimate compares unfavorably to 2016, which included a tax benefit of $40.8 million or ~$0.80 per share. Our price target averages our DCF valuation and a P/E-derived target, which is 35x 2018E EPS of $1.70 discounted to present at 10%. At current prices, the shares have corrected by ~18% from all-time highs after an update on pipeline drug SPN-810 raised risks on timing/approvability. We see this drop as an opportunity to establish positions.”,” FBR & Co’s analyst commented.

Other equities research analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a hold rating to a buy rating and set a $49.00 price objective on the stock in a report on Thursday, July 13th. Cantor Fitzgerald increased their price objective on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a buy rating in a report on Wednesday, July 5th. Jefferies Group LLC increased their price objective on shares of Supernus Pharmaceuticals from $45.00 to $51.00 and gave the stock a buy rating in a report on Wednesday, June 28th. BidaskClub lowered shares of Supernus Pharmaceuticals from a strong-buy rating to a buy rating in a report on Tuesday, July 25th. Finally, Stifel Nicolaus reissued a buy rating and set a $47.00 price objective (up previously from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $48.38.

Shares of Supernus Pharmaceuticals (SUPN) traded down 1.76% during mid-day trading on Thursday, reaching $41.85. 421,091 shares of the company traded hands. The stock has a market capitalization of $2.12 billion, a PE ratio of 21.12 and a beta of 1.30. The stock’s 50 day moving average is $42.84 and its 200 day moving average is $39.71. Supernus Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The business had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. On average, analysts anticipate that Supernus Pharmaceuticals will post $1.04 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/10/20/supernus-pharmaceuticals-inc-supn-receives-new-coverage-from-analysts-at-fbr-co.html.

In other Supernus Pharmaceuticals news, SVP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $49.86, for a total transaction of $249,300.00. Following the transaction, the senior vice president now directly owns 12,500 shares in the company, valued at approximately $623,250. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Gregory S. Patrick sold 50,000 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $47.60, for a total transaction of $2,380,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 153,709 shares of company stock worth $7,223,108. Corporate insiders own 6.70% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Neumeier Poma Investment Counsel LLC lifted its position in Supernus Pharmaceuticals by 1.6% during the 2nd quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock valued at $38,391,000 after purchasing an additional 14,430 shares during the period. Sheets Smith Wealth Management acquired a new position in Supernus Pharmaceuticals during the 2nd quarter valued at about $378,000. Royce & Associates LP lifted its position in Supernus Pharmaceuticals by 22.3% during the 2nd quarter. Royce & Associates LP now owns 159,000 shares of the specialty pharmaceutical company’s stock valued at $6,853,000 after purchasing an additional 29,000 shares during the period. Teachers Advisors LLC lifted its position in Supernus Pharmaceuticals by 6.9% during the 2nd quarter. Teachers Advisors LLC now owns 466,060 shares of the specialty pharmaceutical company’s stock valued at $20,087,000 after purchasing an additional 29,939 shares during the period. Finally, Bank of America Corp DE lifted its position in Supernus Pharmaceuticals by 10.7% during the 1st quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock valued at $11,361,000 after purchasing an additional 35,069 shares during the period. Institutional investors own 95.36% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.